Beijing QL Biopharmaceutical Co.,Ltd
11
2
3
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants
Role: lead
A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants
Role: lead
Efficacy and Safety of ZT006 in Overweight and Obese Participants
Role: lead
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers
Role: lead
A Study of ZT002 in Healthy Participants
Role: collaborator
A Study of ZT002 Injection in Participants With Overweight or Obesity
Role: lead
Dose-escalation and Food Effect Study of ZT006 in Healthy, Overweight and Obese Participants
Role: lead
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
Role: lead
A Study of ZT002 Injection With Subjects With Overweight or Obesity
Role: lead
A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)
Role: lead
A SAD Study of ZT002 Injection in Healthy Participants
Role: lead
All 11 trials loaded